Skip to main navigation Skip to search Skip to main content

The role of nanotechnology for diagnostic and therapy strategies in lung cancer

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    Lung cancer is globally the second most common cancer accounting for millions of deaths each year in both men and women. Early diagnosis is still difficult due to the cancer growing silently in the lung resulting in late diagnosis and high mortality. In recent years, nanotechnology has been advancing the diagnosis and cancer therapy modalities. A number of nanotherapies based around nanoparticles (NPs) have been developed to treat ailments such as pain, infectious diseases, and cancer. Nano-based medicine is providing a pharmacokinetic and pharmacodynamic advantage over current chemotherapy such as bioavailability, intestinal absorption, solubility, and targeted delivery. The progress that has led to the development of emerging cancer therapies in the clinic for the treatment of lung cancer is reaching fruition. Herein, this chapter outlines the current developments in nanomedicine for lung cancer diagnosis and therapy using NPs including liposomes, polymeric NPs, quantum dots, gold NPs, dendrimers, carbon nanotubes, and magnetic NPs.
    Original languageEnglish
    Title of host publicationMedical Radiology
    PublisherSpringer Science and Business Media Deutschland GmbH
    Pages1-18
    DOIs
    Publication statusPublished - 19 Jul 2022

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'The role of nanotechnology for diagnostic and therapy strategies in lung cancer'. Together they form a unique fingerprint.

    Cite this